Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel To Consider Potential Tumor Risk With Fibrocell Science's Wrinkle Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

The Cellular, Tissue and Gene Therapies Advisory Committee meets Oct. 9 to discuss the first cellular product proposed to treat nasolabial facial wrinkles.

You may also be interested in...

Fibrocell's Wrinkle Treatment: FDA Panel Supports Efficacy But Is Mixed On Safety

Advisory committee votes that Laviv (azfibrocel-T) is effective in improving nasolabial fold wrinkles, but that safety data are too limited to be relied upon - especially considering the inevitably widespread off-label use.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts